Business
Paysign, Inc. Reports First Quarter 2025 Financial Results
HENDERSON, Nev., May 08, 2025--Paysign, Inc. Reports First Quarter 2025 Financial Results
About this update from Paysign, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3029,"height":619,"url":"https://media.zenfs.com/en/business-wire.com/eebb60636935c0d9a6867d3ee3a6784d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xe1eG2NRagyMVWUZdncf7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eebb60636935c0d9a6867d3ee3a6784d","width":960,"height":196},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VYPh83iJTnxE9RVBNV5QqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/eebb60636935c0d9a6867d3ee3a6784d","width":1200,"height":245}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024","length":85,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024","length":186,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241","length":180,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma revenue decreased 9.2%","length":261,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Added 14 net patient affordability programs during first quarter 2025, exiting the quarter with 90 active programs; number of processed claims increased over 160% over the same period last year; year-over-year pharma patient affordability revenue increased 260.8%","length":263,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Exited the quarter with $6.85 million of unrestricted cash and zero bank debt while repurchasing 100,000 shares of common stock for $376 thousand","length":145,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"F...